Context Therapeutics修订协议,彻底免除CT-202未来里程碑付款与特许权使用费义务

美股速递
May 18

Context Therapeutics Inc.宣布,已成功修订其关于药物CT-202的许可协议。根据修订条款,公司未来所有与此药物相关的里程碑付款及特许权使用费义务均被完全免除。此项调整显著优化了公司的财务结构,移除了潜在的长期现金流支出,为未来的研发与运营提供了更大的财务灵活性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10